Founded to address critical public health challenges, Brii Biosciences is a biotechnology company with operations in the United States and China. The company's core mission is to develop innovative therapeutics for infectious diseases and central nervous system disorders, particularly in areas with high unmet medical needs and social stigmas. Brii Biosciences focuses on creating first-in-class or different-in-class treatment options to improve patient outcomes and quality of life.

Notable figures associated with Brii Biosciences include experienced scientists and industry leaders who drive its research and development efforts. The company has garnered significant investment from prominent biotech investors, enabling it to advance its robust pipeline of therapies. Brii Biosciences has achieved key milestones in clinical trials and regulatory approvals, making a substantial impact on global health by providing new treatment options for underserved patient populations.